Physician profile
Patrick S Meehan
NPI 1740492040
$1,081.14
in general payments reported to CMS, 2019-2025
16 companies · $204 in 2025
The $204 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $332 · 2020: $31.89 · 2023: $158 · 2024: $355 · 2025: $204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $717.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fisher & Paykel Healthcare INC | $157.95 | 2023 | Fisher & Paykel Healthcare |
| Sentec, INC. | $150.76 | 2025 | |
| Abiomed | $150.00 | 2024 | Impella |
| Intuitive Surgical, INC. | $124.93 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $109.37 | 2019 | |
| Glaxosmithkline, LLC. | $100.58 | 2019 | |
| Sunovion Pharmaceuticals INC. | $65.48 | 2019-2020 | |
| Abbvie INC. | $53.50 | 2025 | |
| Genzyme Corporation | $51.55 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.87 | 2019 | |
| Allergan, INC. | $30.38 | 2019 | |
| Amgen INC. | $28.63 | 2024 | Tezspire |
| Astrazeneca Pharmaceuticals LP | $19.14 | 2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Meehan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.